Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818263 | 0.91 | RAB9A (0.39) | GAAALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL17957243 | 0.88 | ALOX5 (0.36) | SLC6A3ALOX5EPHX2POLBGAA | |
| SCHEMBL2814559 | 0.87 | CHIT1 (0.39) | POLBGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2816898 | 0.86 | EPHX2 (0.38) | EPHX2POLBGAARAB9ASMN1; SMN2 | |
| SCHEMBL2813846 | 0.84 | BLM (0.39) | — | |
| SCHEMBL2814666 | 0.82 | RAF1 (0.38) | POLBALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL17957294 | 0.81 | HTT (0.41) | POLBGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL2816391 | 0.80 | COPS5 (0.39) | GAAALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL2814901 | 0.79 | RAB9A (0.40) | POLBGAARAB9ASMN1; SMN2MEN1 | |
| SCHEMBL17957288 | 0.79 | RAB9A (0.37) | GAAALDH1A1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193122-B1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-08-03 | — | — | EP | claimed |
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | claimed |
| EP-2193122-B1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | SDHA, SDHB, TPD52L2 | SLC6A3 1682/4885ALOX5 4251/4885EPHX2 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.